Evidence map›Paper›PMID 25637587›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2015

Adverse Events Following Measles, Mumps, and Rubella Vaccine in Adults Reported to the Vaccine Adverse Event Reporting System (VAERS), 2003-2013.

Lakshmi Sukumaran, Michael M McNeil, Pedro L Moro, Paige W Lewis, Scott K Winiecki, Tom T Shimabukuro

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 2 pooled it
8.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 2 syntheses or guidelines pooled it, 59 citations in OpenAlex.

  1. Guideline
  2. Guideline
  3. Trial
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Observational
  15. Article
  16. Review
  17. [Post-vaccine exanthema in a patient with the IgG4 related disease].Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2018
    Article
  18. Observational
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Lakshmi SukumaranImmunization Safety Office, Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention Emory University School of Medicine, Atlanta, Georgia.
Michael M McNeilImmunization Safety Office, Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention.
Pedro L MoroImmunization Safety Office, Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention.
Paige W LewisImmunization Safety Office, Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention.
Scott K WinieckiOffice of Biostatistics and Epidemiology, Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland.
Tom T ShimabukuroImmunization Safety Office, Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention.
Centers for Disease Control and Prevention · UGCenter for Biologics Evaluation and Research · US

Funding

Training a New Generation of VaccinologistsT32AI074492 · NIAID · EMORY UNIVERSITY · PI Rama Rao Amara, Benjamin A Lopman · 2009 to 2026
$6.4M
NIAID NIH HHS T32 AI074492NIAID NIH HHS T32AI074492
6 · The paper itself

Abstract

backgroundLimited data exist on the safety of the measles, mumps, and rubella (MMR) vaccine in adults. We reviewed reports of adverse events (AEs) to the Vaccine Adverse Event Reporting System (VAERS) to assess safety in this previously understudied group.

methodsVAERS is the national spontaneous vaccine safety surveillance system coadministered by the Centers for Disease Control and Prevention and the US Food and Drug Administration. We searched the VAERS database for US reports of adults aged ≥19 years who received the MMR vaccine from 1 January 2003 to 31 July 2013. We clinically reviewed reports and available medical records for serious AEs, pregnancy reports, and reports for selected prespecified outcomes.

resultsDuring this period, VAERS received 3175 US reports after MMR vaccine in adults. Of these, 168 (5%) were classified as serious, including 7 reports of death. Females accounted for 77% of reports. The most common signs and symptoms for all reports were pyrexia (19%), rash (17%), pain (13%), and arthralgia (13%). We did not detect any new safety findings in empirical Bayesian data mining. We identified 131 reports of MMR vaccine administered to a pregnant woman; the majority of these vaccinations were in the first trimester and in 83 (62%), no AE was reported.

conclusionsIn our review of VAERS data, we did not detect any new or unexpected safety concerns for MMR vaccination in adults. We identified reports of pregnant women exposed to MMR, which is a group in whom the vaccine is contraindicated, suggesting the need for continued provider education on vaccine recommendations and screening.

Indexed as

AdultAgedAged, 80 and overArthralgiaCenters for Disease Control and Prevention, U.S.Drug-Related Side Effects and Adverse ReactionsExanthemaFemaleFeverHumansIncidenceMaleMeasles-Mumps-Rubella VaccineMiddle AgedPainPregnancyMeasles-Mumps-Rubella VaccinemeaslesMMR vaccinemumpsrubellaVaccine Adverse Event Reporting System (VAERS)

Identifiers

PMID25637587
PMCPMC4447805
OpenAlexW2147973036

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.